The phase 1 study is intended to characterize the safety, tolerability, and feasibility of intravesical administration of UGN-501.
Commentary|Articles|July 21, 2026
Study shows durable 3-year outcomes with first-line gemcitabine/docetaxel in NMIBC
Author(s)Tyler Garman, MD
Fact checked by: Hannah Clarke, Cheney Gazzam Baltz
Tyler S. Garman, MD, highlights phase 2 data on intravesical gemcitabine and docetaxel as first-line treatment of BCG-naive NMIBC.
Advertisement
Advertisement
As ongoing BCG shortages continue to challenge the management of high-risk non–muscle-invasive bladder cancer (NMIBC), interest has grown in alternative first-line intravesical treatment strategies. Updated findings from the phase 2 GEMDCE trial (NCT04386746) of first-line intravesical gemcitabine and docetaxel (gem/doce) showed durable 3-year high-grade recurrence-free survival, no progression during treatment, and a manageable safety profile in patients with BCG-naive high-risk NMIBC.1
Related to this article
Paras H. Shah, MD, recaps data on emerging agents in high-risk NMIBC from the 2026 AUA North Central Section Meeting.
Five-year follow-up data show durable responses with UGN-101 in patients with low-grade upper tract urothelial carcinoma who achieved an initial complete response.
Topline results are expected in November 2026 ahead of a planned sBLA submission.
In a POTOMAC subgroup analysis, durvalumab plus BCG reduced the risk of high-risk recurrence or death by 44% vs BCG alone in patients with papillary-only, BCG-naive NMIBC.
Andrea Necchi, MD, discusses how results from the CA017-078 trials compares with other perioperative immunotherapy trials in muscle-invasive bladder cancer.
Final phase 3 CA017-078 data show perioperative nivolumab plus GC did not significantly improve pCR (39.1% vs 29.6%) or EFS (HR, 0.94) vs GC alone in MIBC.
Perioperative durvalumab (Imfinzi) plus neoadjuvant enfortumab vedotin-ejfv (Padcev) cut the risk of EFS events by 49% and death by 42% in cisplatin-ineligible MIBC.
Advertisement
Advertisement